Trial Profile
EXpanded CELL ENdocardiac Transplantation (EXCELLENT)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 01 Apr 2024
Price :
$35
*
At a glance
- Drugs Endothelial stem cell therapy CellProThera (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions; First in man
- Acronyms EXCELLENT
- Sponsors CellProthera
- 27 Mar 2024 According to a BioCardia media release, results from this trial expected soon.
- 28 Sep 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Sep 2023 According to a BioCardia media release, update on licensing / partnerships and completion of enrollment in this trial expected in Q4 2023.